This study is to obtain the characteristics and treatment pattern of the unresectable HCC patients who are candidates for systemic therapy and in whom a decision to treat with sorafenib from early stage of TACE treatment course (concomitantly use no later than the 3rd TACE procedure) has been made under real-life practice conditions.this study will also conclude the safety and effectiveness of combination in uHCC patients.

Inclusion Criteria:

• Patients with histologically/ cytologically documented or radiographically diagnosed unresectable HCC who are candidates for systemic therapy and for whom a decision to treat with sorafenib has been made. Radiographic diagnosis needs typical findings of HCC by radiographic method i.e. on multi-dimensional dynamic CT, CT hepatic arteriography (CTHA)/CT arterial portography (CTAP) or MRI;
• Patients receive the first dose of sorafenib no later than 1 week (<=7days) after the 3rd TACE procedure
• Patients did not receive other prior systemic treatment by using target therapy
• Patients must sign the informed consent form;
• Patients must have a life expectancy of at least 3 months;
• The physician must be willing to complete and submit all CRFs;
• The physician must be willing to submit to a site audit with verification of source documents and validation of data reported;

Exclusion Criteria:

• The first dose of sorafenib 7 days after the 3nd TACE procedure
• Exclusion criteria must follow the approved local product information

Unresectable HCC patients and be candidates for concomitantly systemic therapy with sorafenib + TACE. Considering the local practice and possible clinical benefits, sorafenib should not be initiated later than 7 days after the 3rd TACE course. No prior tartgeted therapy.